A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether talquetamab is an effective
treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple
myeloma. All participants in this study will have already received the BCMA CAR T-cell
therapy ide-cel for their disease.